Emerging findings surround retatrutide, a dual agonist for GLP-1R and GIP, demonstrate promising potential in managing excess body fat and related metabolic-related conditions. Preliminary studies indicate considerable https://retatrutideresearchlab.co.uk/product/ozempic-025-mg-peptide/